'Ranbaxy will see operating losses post USFDA ban'

Surjit Pal, analyst at Prabhudas Lilladher, reacting on the USFDA ban on drug imports from Ranbaxy plant in India, said that this will lead to operating losses for the company.
Share this Video
appinstlBnr
Open in App
Success
This article has been saved